CASE STUDIES

Working with Start-ups/SMEs (Acuitive)

Rectangle 15941

CITREGEN™ A novel bioactive platform technology for musculoskeletal applications. A journey from validation through to FDA clearance. In collaboration with CÚRAM, Acuitive Technologies, Inc. has validated the scientific potential of their groundbreaking bioactive CITREGEN™ platform technology to accelerate tissue healing and address challenges associated with currently available biodegradable devices across various musculoskeletal applications.

  • Rectangle 16461

    Led by CÚRAM FI

    Manus Biggs

Rectangle 15632

Significant investment raised by Acuitive for expanding their citrate-based biomaterial portfolio and their recent FDA 510k clearance as a direct result of this collaboration.

Screenshot

Proved the bioactive potential of novel biomimetic citrate-based polymer technology CITREGEN™.

Molecular mechanisms underlying biomimicry and anti-inflammatory responses of CITREGEN™ were elucidated

Results indicated versatility of CITREGEN™ in bone repair applications and its capacity to reduce the onset of inflammation

  • wpml-ls-flag
  • wpml-ls-flag
Back to Top